Annex I

Scientific conclusions and grounds for the variation to the terms of the Marketing Authorisation(s)

Scientific conclusions

Taking into account the PRAC Assessment Report on the PSUR(s) for phloroglucinol, phloroglucinol / trimethylphloroglucinol, the scientific conclusions are as follows:

Based on the new provided data regarding occurrence of *"Acute Generalized Exanthematous Pustulosis* "(AGEP) (SOC "Skin and subcutaneous tissue disorders "), it is recommended to update section 4.8 "Adverse Reactions" of the SmPC and section 4 of the package leaflet of Phloroglucinol (PG) and phloroglucinol/trimethylphloroglucinol (PG/TPG) containing products.

Rationale: A compelling published case (Brahimi N and al. Ann Dermatol. Venereol. 2017 Jun) of Acute Generalized Exanthematous Pustulosis has been submitted. The clinical manifestations that support the diagnosis of AGEP (AGEP score calculator=10 then definite AGEP), the plausible temporal association between the administration of phloroglucinol (PG) and the event onset, the favorable positive dechallenge and rechallenge, constitutes evidences of the likely causality of PG. Therefore product informations for PG and PG/TPG SmPC and the Package Leaflet, accordingly, should be updated.

The CMDh agrees with the scientific conclusions made by the PRAC.

Grounds for the variation to the terms of the Marketing Authorisation(s)

On the basis of the scientific conclusions for phloroglucinol, phloroglucinol / trimethylphloroglucinol the CMDh is of the opinion that the benefit-risk balance of the medicinal product(s) containing phloroglucinol, phloroglucinol / trimethylphloroglucinol is unchanged subject to the proposed changes to the product information.

The CMDh reaches the position that the marketing authorisation(s) of products in the scope of this single PSUR assessment should be varied. To the extent that additional medicinal products containing phloroglucinol, phloroglucinol / trimethylphloroglucinol are currently authorised in the EU or are subject to future authorisation procedures in the EU, the CMDh recommends that the concerned Member States and applicant/marketing authorisation holders take due consideration of this CMDh position.

Annex II

Amendments to the product information of the nationally authorised medicinal product(s)

Amendments to be included in the relevant sections of the Product Information (new text underlined and in bold, deleted text ~~strike through~~)

Summary of Product Characteristics

- Section 4.8

  Add in the current Tabulated Summary of Adverse Reactions

System Organ Class	Adverse reaction-Preferred term	Frequency
Skin and subcutaneous tissue disorders	*Acute Generalised Exanthematous Pustulosis*	*Unknown*

Package Leaflet

- Section 4 Possible Side effects

  Frequency not known:

  - A red, scaly widespread rash with bumps under the skin and blisters accompanied by fever at the initiation of treatment (acute generalised exanthematous pustulosis).

  Stop using this medicine if you develop these symptoms and contact your doctor or seek medical attention immediately.

Annex III

Timetable for the implementation of this position

Timetable for the implementation of this position

Adoption of CMDh position:	May 2019 CMDh meeting
Transmission to National Competent Authorities of the translations of the annexes to the position:	11 July 2019
Implementation of the position by the Member States (submission of the variation by the Marketing Authorisation Holder):	09 September 2019